Bloodstream infection

info-atbvac > Bloodstream infection

Does short course adjunctive aminoglycoside therapy improve mortality in Gram-negative bloodstream infection? ( J W Timotëus Deelen et al. )

Short course aminoglycosides as adjunctive empiric therapy in patients with Gram negative bloodstream infection, a cohort study.

23 juin | Dr Jean-Pierre Bru

Short-course combination therapy with aminoglycoside in patients with sepsis or septic shock is still a matter of debate. Arguments for … Suite

Risk factors of multidrug resistance of P. aeruginosa in neutropenic patients, identifications and building up a clinical prediction model ( C. Gudiol et al. )

Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

15 mai | Dr Olivier Leroy

Pseudomonas aeruginosa (PA) has classically been one of the most important causes of severe sepsis and death among cancer patients … Suite

Can bacteremia due to glycopeptide-susceptible Enterococcus faecium be treated with linezolid? ( Echeverria-Esnal D. et al. )

Linezolid versus glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteremia: A propensity-score matched comparative study.

17 déc | Dr Philippe Lesprit

Vancomycin is the first-line treatment of glycopeptide (GP)-susceptible E. faecium (GSEF)-bloodstream infections (BSI) except for the rare amoxicillin-sensitive strains. GP … Suite